Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 9/2022

18-03-2022 | Ulcerative Colitis | Editorial

Spotlight on Cardiovascular Risk Assessment in Patients with Inflammatory Bowel Disease

Authors: Jasmijn A. M. Sleutjes, Jeanine E. Roeters van Lennep, Annemarie C. de Vries

Published in: Digestive Diseases and Sciences | Issue 9/2022

Login to get access

Excerpt

Evidence is mounting that patients with inflammatory bowel disease (IBD) have an elevated risk of vascular complications, comprised of venous thromboembolism (VTE) and arterial cardiovascular disease (CVD). According to meta-analyses, the risk of VTE in patients with IBD is 2.5 times higher and the risk of CVD 1.2 times higher than the risk in the general population [1, 2]. These vascular complications probably result from a cumulative effect of traditional risk factors for VTE and CVD, combined with the chronic systemic inflammation typical of IBD. …
Literature
1.
Fumery M et al. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies. J Crohns Colitis 2014;8:469–479.CrossRef
2.
Sun HH, Tian F. Inflammatory bowel disease and cardiovascular disease incidence and mortality: A meta-analysis. Eur J Prev Cardiol 2018;25:1623–1631.CrossRef
3.
4.
Konstantinides SV et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020;41:543–603.CrossRef
5.
6.
Harbord M et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2016;10:239–254.CrossRef
7.
Nguyen GC et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014;146:835–848.CrossRef
8.
Tinsley A et al. A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol 2013;47:e1–e6.CrossRef
9.
Dwyer JP et al. Venous thromboembolism and underutilisation of anticoagulant thromboprophylaxis in hospitalised patients with inflammatory bowel disease. Intern Med J 2014;44:779–784.CrossRef
10.
Tinsley A et al. Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: Results from a tertiary care center. J Crohns Colitis 2013;7:e635–e640.CrossRef
11.
Nguyen GC et al. Quality of care and outcomes among hospitalized inflammatory bowel disease patients: A multicenter retrospective study. Inflamm Bowel Dis 2017;23:695–701.CrossRef
12.
Faye AS et al. Minor hematochezia decreases use of venous thromboembolism prophylaxis in patients with inflammatory bowel disease. Inflamm Bowel Dis 2020;26:1394–1400.CrossRef
13.
Ra G et al. Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. J Crohns Colitis 2013;7:e479–e485.CrossRef
14.
Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol 2006;1:297–329.CrossRef
15.
Wu GC et al. Subclinical atherosclerosis in patients with inflammatory bowel diseases: A systematic review and meta-analysis. Angiology 2017;68:447–461.CrossRef
16.
Piepoli MF et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Rev Esp Cardiol (Engl Ed) 2016;69:939.
17.
Agca R et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17–28.CrossRef
18.
Emanuel G et al. Cardiovascular risk assessment and treatment in chronic inflammatory disorders in primary care. Heart 2016;102:1957–1962.CrossRef
19.
Yarur AJ et al. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol 2011;106:741–747.CrossRef
20.
Aggarwal A et al. Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease. Inflamm Bowel Dis 2014;20:1593–1601.CrossRef
21.
Biondi RB et al. Cardiovascular risk in individuals with inflammatory bowel disease. Clin Exp Gastroenterol 2020;13:107–113.CrossRef
22.
Aarestrup J et al. Cardiovascular risk profile among patients with inflammatory bowel disease: A population-based study of more than 100 000 individuals. J Crohns Colitis 2019;13:319–323.CrossRef
23.
Agrawal T et al. Prevalence of cardiovascular risk factors in a nationally representative adult population with inflammatory bowel disease without atherosclerotic cardiovascular disease. Am J Prev Cardiol 2021;6:100171.CrossRef
24.
Sleutjes JAM et al. Systematic review with meta-analysis: Effect of inflammatory bowel disease therapy on lipid levels. Aliment Pharmacol Ther 2021;54:999–1012.CrossRef
Metadata
Title
Spotlight on Cardiovascular Risk Assessment in Patients with Inflammatory Bowel Disease
Authors
Jasmijn A. M. Sleutjes
Jeanine E. Roeters van Lennep
Annemarie C. de Vries
Publication date
18-03-2022
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07449-0

Other articles of this Issue 9/2022

Digestive Diseases and Sciences 9/2022 Go to the issue

FELLOWS AND YOUNG GIS SECTION

Advanced Fellowship Training in IBD: A Worthwhile Fourth Year

PROFILES AND PERSPECTIVES

DDS Profile: Daniel Hollander, MD

Original Article

Troponin C-1 Activated by E2F1 Accelerates Gastric Cancer Progression via Regulating TGF-β/Smad Signaling

Original Article

Utility of Cyst Fluid Carcinoembryonic Antigen in Differentiating Mucinous and Non-mucinous Pancreatic Cysts: An Updated Meta-Analysis

PROFILES AND PERSPECTIVES

DDS Perspective: Crohn’s Disease and Increased Intestinal Permeability—Initial Demonstration and Birth Pains

Original Article

Risk Score Using Demographic and Clinical Risk Factors Predicts Gastric Intestinal Metaplasia Risk in a U.S. Population
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits